Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.35
+0.09 (1.24%)
Feb 17, 2026, 9:38 AM EST - Market open

Kyverna Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21
420161---
Enterprise Value
249-151---
Last Close Price
7.263.74---
PB Ratio
2.090.61---
P/TBV Ratio
2.730.61---
Debt / Equity Ratio
0.030.030.190.230.09
Net Debt / Equity Ratio
-1.09-1.04-0.99-0.87-1.13
Net Debt / EBITDA Ratio
0.981.960.791.432.74
Net Debt / FCF Ratio
1.052.380.911.113.01
Asset Turnover
---0.09-
Quick Ratio
5.058.472.904.294.78
Current Ratio
5.168.613.064.464.84
Return on Equity (ROE)
-70.82%-80.74%-125.95%-52.95%-
Return on Assets (ROA)
-40.75%-46.93%-54.89%-24.10%-
Return on Capital Employed (ROCE)
-111.90%-52.60%-112.80%-53.50%-37.90%
Earnings Yield
-38.82%-78.95%---
FCF Yield
-38.04%-72.13%---
Buyback Yield / Dilution
-56.07%-5590.81%-47.89%-71.30%-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q